Daratumumab for the treating high-risk smouldering multiple myeloma

Daratumumab is in clinical development for high-risk smouldering multiple myeloma (SMM). SMM is an early form of myeloma which usually progresses to active myeloma, but at a slow rate. SMM is a precancerous condition that changes certain proteins in blood and/or increases plasma cells in the bone marrow but does not cause symptoms of disease. SSM is often diagnosed by chance, following a routine health check or blood tests for another condition. Within 5 years, about half of those diagnosed with the condition will develop multiple myeloma (MM). MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of red and white blood cells and platelets.